Advanced Oncotherapy PLC Schedule 2(g) Disclosure (0355O)

TIDMAVO

RNS Number : 0355O

Advanced Oncotherapy PLC

24 January 2019

24 January 2019

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Schedule 2(g) Disclosure

Advanced Oncotherapy (AIM: AVO), the developer of a next-generation proton therapy system for cancer treatment, announces the following updates to disclosure in relation to Dr Michael Sinclair, Executive Chairman of the Company, pursuant to AIM Rule 17 and Schedule 2(g)(iii) to (viii) of the AIM Rules.

Michael Sinclair was appointed as a director of SIX-13 LIMITED (UK registration number: 03793994) on 14 March 2000. The company entered into voluntary creditors liquidation on 13 December 2007 and was dissolved on 19 June 2010. Michael Sinclair was the principal creditor.

Michael Sinclair was appointed as a director of YOOPLAY LIMITED (UK registration number: 04211249), a wholly owned subsidiary of YOOMEDIA PLC, on 6 January 2004. The company entered into voluntary creditors liquidation on 30 November 2006 and was dissolved on 23 October 2007. YOOMEDIA PLC was the principal creditor.

For further information, please contact:

 
  Advanced Oncotherapy Plc                                       www.avoplc.com 
  Dr. Michael Sinclair, Executive                         Tel: [phone] 
   Chairman 
  Nicolas Serandour, CEO 
 
  Stockdale Securities (Nomad & 
   Joint Broker) 
  Antonio Bossi                                           Tel: [phone] 
 
  Stifel Nicolaus Europe (Joint 
   Broker) 
  Jonathan Senior                                         Tel: [phone] 
 
  Walbrook PR (Financial PR & IR)   Tel: [phone] or [e-mail] 
  Paul McManus / Anna Dunphy                   Mob: [phone] / Mob: +44 
                                                                   7876 741 001 
 

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCLLFLFLLISFIA

(END) Dow Jones Newswires

January 24, 2019 07:14 ET (12:14 GMT)